Healthcare entity
Every one of those 1 sits in a single category, market-trends. Dr. Reddy's Laboratories is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 8 runs above the beat's 6.3 for that window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Dr. Reddy's Laboratories is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 8 runs above the beat's 6.3 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.9 for the same window. We currently track 1 Healthcare story that mention Cipla, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cipla. Shared-story counts are live from our verified record — not editorial picks.
India's pharmaceutical sector is poised to disrupt the high-cost weight-loss drug market by introducing affordable generic versions of GLP-1 agonists. This move could democratize access to obesity treatments globally while challenging the pricing power of Western pharmaceutical giants.
Source: myjoyonline.com · ghanaiantimes.com.gh
Cipla is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
